Abstract

Plasminogen activator inhibitor-1 (PAI-1) regulates fibrinolysis by inhibiting tissue type plasminogen activator (t-PA). Fibrinogen, heparin, and vitronectin enhance the rate of inhibition of t-PA by PAI-1. Kinetic studies indicate that both fibrinogen and heparin increase the second-order inhibition constant by a maximum of approximately 4-fold, whereas vitronectin increases the rate constant by a maximum of approximately 6-fold. The dissociation constants of fibrinogen, heparin, and vitronectin for the inhibition reaction were 200 nM, 20 nM, and 600 pM, respectively. In addition, PAI-1 inhibition of t-PA may be regulated by the presence of lipoprotein(a) (Lp(a)). Previous studies demonstrated that Lp(a) competes with plasminogen for the active site of fibrinogen- and heparin-bound t-PA. Kinetic studies described here demonstrate that Lp(a) prevents the inhibition of t-PA by PAI-1 in the presence of fibrinogen and heparin, but has no effect on the reaction in the presence of vitronectin or in the absence of either fibrinogen or heparin. The data suggest that fibrinogen and heparin may enhance the rate of inhibition through an interaction with t-PA, and that vitronectin may enhance the inhibition through an interaction with PAI-1. In addition, these experiments indicate that Lp(a) may regulate fibrinolysis by competing with PAI-1 and plasminogen for fibrinogen- and heparin-bound t-PA. These data suggest that PAI-1 inhibition of t-PA in vivo is primarily mediated via interaction with fibrinogen, heparin, vitronectin, and Lp(a), and therefore, the functional levels of PAI-1 activity in the vasculature may be regulated by the presence of these components.

Highlights

  • From the Departments of Pathology and Biochemistry, Duke Uniuersity Medical Center, Durham, North Carolina 27710 and the $Department of Pharmacology, MerckSharp & Dohme Research Laboratories, West Point, Pennsylvania 19486

  • The inhibitor is released into the enhance therate of inhibition of t-PA by PAI- 1.Kinetic vasculature by endothelial cells [1,2,3], platelets [4, 5], hepastudies indicate that both fibrinogen and heparin increase the second-order inhibition constant by a maximum of approximately 4-fold, whereasvitronectin increases therate constant by a maximum of approximately &fold

  • Recent studies an interaction with Plasminogen activator inhibitor-1 (PAI-1). These experi- suggest that several components of the vasculature such as ments indicatethat Lp(a) may regulate fibrinolysisby competingwith PAI-1and plasminogen for fibrinogenand heparin-bound t-PA. These data suggest that PAI1inhibition of t-PA in vivo is primarily mediated via interaction with fibrinogen, heparin, vitronectin, and Lp(a), and the functional levels of PAI-1 fibrinogen and vitronectin may affect the PAI-1 inhibition of t-PA [19,20,21,22]

Read more

Summary

Introduction

From the Departments of Pathology and Biochemistry, Duke Uniuersity Medical Center, Durham, North Carolina 27710 and the $Department of Pharmacology, MerckSharp & Dohme Research Laboratories, West Point, Pennsylvania 19486. Both fibrinogen and heparin enhance the catalytic rate of t-PA-mediated plasminogen activation [23,24,25,26,27], providing a means for enhanced enzyme inhibition. We provide a detailed analysis of the effects of fibrinogen, heparin, vitronectin, and Lp(a) on the rateof t-PA inhibition by PAI-1.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.